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Spermatic cord lymphoma is a rare lethal disease. It has a poor prognosis even in stage I or II disease when treated locally,
therefore, multidisciplinary treatment for early stage is recommended. On the other hand, the treatment of choice for stage III or
IV spermatic cord lymphoma remains to be determined. It is said that spermatic cord lymphoma is clinicopathologically similar
to primary testicular lymphoma, therefore the treatment of spermatic cord lymphoma has often been determined by reference to
the recommended treatment for primary testicular lymphoma. Here we report a new case of spermatic cord lymphoma, which
was found in stage IV disease. We also review thirty-three cases which have been reported as spermatic cord lymphoma to date,
and discuss treatment options.
1.Introduction
Spermatic cord lymphoma is a rare lethal disease. To our
knowledge, searching both English and Japanese literature,
only thirty-three cases including our case have been reported
[1–8]. It has a poor prognosis even in stage I disease when
treated locally, therefore, multidisciplinary treatment for
early stage is recommended. Here we report a new case of
spermatic cord lymphoma, which was found in stage IV dis-
ease.Wealsoreviewliteratureanddiscusstreatmentoptions.
2.CaseReport
In July 2010, a 62-year-old man visited an urologist with a
complaint of a left intrascrotal mass and was placed under
clinical observation without treatment. Two months later, a
swellingoftherighttonsilappeared,andhevisitedanotorhi-
nolaryngologist. After a biopsy of the right tonsil, he was
diagnosed with diﬀuse large B-cell lymphoma (DLBCL) and
was admitted to our hospital. Physical examination showed
that the right tonsil swelled up beyond the midline, right
cervical and left supraclavian lymph nodes were palpable,
and a 50-mm mass existed along the left spermatic cord.
He also had night sweats. In the blood examination, high
levels of serum soluble interleukin-2 receptor were detected
(5290U/mL). Ultrasonography showed a 50mm tumorous
lesion in maximum diameter in the left spermatic cord and a
5mm mass in the right spermatic cord, respectively. Com-
puted tomographic scan (CT) showed the swelling of the
right tonsil and the enlargement of right cervical, left supra-
clavian, and para-aortic lymph nodes. 67Ga scintigraphy
showed intense uptake in the same lesions which were
detectedinCT,butnouptakeingroins(Figure 1).Bonemar-
row aspiration showed a few large atypical cells that were
positive for CD20 and negative for CD3, which suggests
the invasion of lymphoma to the bone marrow. Based on
these ﬁndings, he was clinically diagnosed as DLBCL at stage
IVB (Ann Arbor Staging). In December 2010, he under-
went left radical orchiectomy for conﬁrming the diagnosis
and mass reduction. Macroscopically, a white 67mm tumor
in maximum diameter existed around the left spermatic
cord, but the testis and the epididymis were not involved
(Figure 2).Itconsistedofproliferativelargeatypicallympho-
cytes (Figure 3). Immunohistochemistry revealed that the2 Case Reports in Medicine
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Figure 1: Computed tomographic scan (CT) showing the swelling of the right tonsil and the enlargement of right cervical, left supraclavian,
and para-aortic lymph nodes. 67Ga scintigraphy showing intense uptake in the same lesions which were detected in CT.
Figure 2: Gross appearance of the surgical specimen showing a
white 67mm tumor around the left spermatic cord.
tumor cells were positive for CD20 and negative for CD3.
Histopathological diagnosis was DLBCL of the left sper-
matic cord. As adjuvant therapy, he completed both 6 cycles
Figure 3: Microscopic features of the tumor consisting of prolifer-
ative large atypical lymphocytes.
of rituximab added to cyclophosphamide, doxorubicin, vin-
cristine, and prednisone (R-CHOP) and 4 cycles of intrathe-
cal methotrexate (IT-MTX) for central nervous systemCase Reports in Medicine 3
Table 1: Reported cases of spermatic cord lymphoma.
Author Age, y Stage Histology Immuno-phenotype Initial
treatment Survival, mo
1934 Fresnais 73 IE LS NA O DOD, 5
1936 Slotkin 36 IE LS NA O DOD, 1
1949 Hector 64 IE RES NA O DOD, 62
1954 Wetterwald 49 IIE LB NA O DOD, 1
1957 Pelot 21 IE RS NA O, RT DOD, 12
1970 Bologna 42 IE LRS NA O, RT DOD, 6
1970 Gotou 57 IE RS NA O, RT NA
1972 Iwata 30 IIE LS NA O, CT DOD, 3
1972 Katou 75 III RS NA O, CT DOD, 3
1980 Karapandov 57 IE CB/CC NA O, RT NA
1982 Guena 46 IE CB/CC NA NA NA
1982 Satou 49 IE Burkitt B O, CT NA
1986 Hautzer 54 IE CBD NA O DOD, 7
1986 Hanada 74 IE DLC NA O DOD, 5
1989 Zwanger-Mendelson 20 IV Burkitt B O DOD, 1
1989 Ooyama 66 IIE DLC NA O, CT NA
1990 D’Abrosca 89 IE CBD NA NA DOD, NA
1990 Nishimura 47 IIE DLC NA O, CT NA
1994 M¨ oller 48 IV CBD B NA DOD, 8
1994 Kawanishi 66 IE DMC NA O, CT, RT NA
1994 Asanuma 78 IE DLC NA CT NA
1994 Oonishi 76 IE DMC NA O NA
1996 Lands 57 IE DLC B O DOD, 26
1997 Umehara 78 IE DLC NA O NA
1998 Ichiyanagi 77 IIE DLC B O, CT DOD, 10
2001 Okabe 76 IE DMC B O DOD, 40
2007 Kawano 57 IIE DLBCL B O, CT NA
2008 Nakano 54 IVA DLBCL B O, CT DOD, 5
2009 Natsuizaka 75 IE DLBCL B O, CT NA
2009 Almeida 71 IE DLBCL B O, CT NA
2009 Suzuki 74 IIIA DLBCL B O, CT DOD, 13
2009 Asano 71 IE DLBCL B O, CT NA
2011 Our case 62 IVB DLBCL B O, CT, RT, IT NA
O, orchiectomy; CT, chemotherapy; RT, radiotherapy; IT, intrathecal chemotherapy; CBD, centroblastic diﬀuse; CB/CC, centroblastic/centrocytic; LB,
lymphoblastic;LS,lymphosarcoma;RS,reticulosarcoma;LRS,lymphoreticulosarcoma;RES,reticuloendotheliosarcoma;DLC,diﬀuselargecell;DMC,diﬀuse
medium cell; DLBCL, diﬀuse large B-cell lymphoma; mo, months; NA, not available; DOD, died of disease.
(CNS) prophylaxis. Then, he also underwent radiotherapy
(RT) to the right testis for prophylaxis of contralateral testic-
ular relapse. CT performed 4 months after the orchiectomy
showed that all lesions either disappeared or reduced, and
that there was no new lesions.
3. Discussion
Male gonadal involvement is relatively uncommon in malig-
nant lymphoma. Of these lymphomas, testicular lympho-
ma is the most frequent, accounting about 1% of all
nonHodgkin’slymphomas[9].Ontheotherhand,spermatic
cord lymphoma is very rare, and to the best of our know-
ledge, only thirty-three cases including our own case have
been reported (Table 1)[ 1–8]. The patients ranged in age
from 20 to 89 years (mean age, 60-year-old). Middle-aged
men (14 out of 33 cases) and older men (15 out of 33
cases) were mainly aﬀected [10]. Most cases were stage I
disease at the time of diagnosis (stage I, 21 cases; stage II,
6 cases; stage III, 2 cases; stage IV, 4 cases), nevertheless,
theyapparentlyhave apoor prognosis (mediansurvival,12.2
months). Our case was already in stage IV at presentation. In
general,itisdiﬃculttodetecttheprimarysitewhenapatient
with malignant lymphoma has multiple lesions. However,
the ﬁrst manifestation of our case was the spermatic
c o r dt u m o r .S p e r m a t i cc o r dl y m p h o m ah a sat e n d e n c yt o4 Case Reports in Medicine
spread or relapse towards para-aortic lymph nodes, while
lymphomas derived from diﬀerent primary lesions hardly
metastasize to a spermatic cord in an early stage [5]. There-
fore, we assumed the primary site in our case might be the
spermaticcord.Histologicallyreviewing,intermediate-grade
lymphomas (Working Formulation), centroblast or cen-
troblastic-centrocytic lymphomas (Kiel classiﬁcation), and
DLBCL(WHOclassiﬁcation)weremostfrequentlyobserved,
excepttwocaseswhichsuﬀeredfromBurkitt’s subtype[1,4].
All cases that the immunophenotypical study was performed
showed a B-cell phenotype.
It is said that spermatic cord lymphoma is clinicopatho-
logically similar to primary testicular lymphoma (PTL). PTL
is a potentially fatal disease second only to primary brain
lymphoma; median survival is between 12 and 24 months
[9]. It is due to failures in contralateral testis, CNS, and
extranodal sites. Recently, an international phase II trial
showed that the recommended ﬁrst-line treatment for stage
I or II PTL is orchiectomy followed by R-CHOP, IT-MTX,
and RT to the contralateral testis [10]. In the same way, it
has been said that multidisciplinary treatments should be
given in early staged spermatic cord lymphoma, but actually
was not. Reviewing reported cases of stage I spermatic cord
lymphoma, the initial treatment was only orchiectomy with
or without RT by the 1980s, and the ratio of combining
chemotherapy or not has become half and half since the
1990s. No case except ours underwent IT-MTX. Median sur-
vival of stage I spermatic cord lymphoma treated only orchi-
ectomy with or without RT was 18.2 months, while 5-year
overall survival rates of early staged PTL treated multi-
disciplinarily were 85% in the recent trial [10]. It suggests
that combined treatment with R-CHOP, IT-MTX, and RT to
the contralateral testis will attribute a better outcome in early
staged spermatic cord lymphoma.
On the other hand, the treatment of choice for stage III
or IV disease in spermatic cord lymphoma still remains to be
determined. For advanced PTL, the recommended ﬁrst-line
treatmentisR-CHOP,howeveramediansurvivaloflessthan
six months is reported [9]. Despite a higher rate of relapse
in the contralateral testis (up to 50% of patients), RT to the
contralateral testis is recommended by some authors, while
others propose RT only for symptomatic patients or in the
case of bulky disease. IT-MTX to prevent CNS relapse, which
occurs in approximately 50% of patients, is also considered
in patients achieving complete remission.
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